ZA985410B - Use of somatostatin agonists and antagonists for treating diseases related to the eye - Google Patents

Use of somatostatin agonists and antagonists for treating diseases related to the eye

Info

Publication number
ZA985410B
ZA985410B ZA985410A ZA985410A ZA985410B ZA 985410 B ZA985410 B ZA 985410B ZA 985410 A ZA985410 A ZA 985410A ZA 985410 A ZA985410 A ZA 985410A ZA 985410 B ZA985410 B ZA 985410B
Authority
ZA
South Africa
Prior art keywords
antagonists
eye
treating diseases
diseases related
somatostatin receptor
Prior art date
Application number
ZA985410A
Other languages
English (en)
Inventor
Michael Ankersen
Carsten Enggaard Stidsen
Michael Albert Crider
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA985410B publication Critical patent/ZA985410B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
ZA985410A 1997-06-24 1998-06-22 Use of somatostatin agonists and antagonists for treating diseases related to the eye ZA985410B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK74797 1997-06-24
US5130097P 1997-06-30 1997-06-30

Publications (1)

Publication Number Publication Date
ZA985410B true ZA985410B (en) 1999-01-04

Family

ID=26064570

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA985410A ZA985410B (en) 1997-06-24 1998-06-22 Use of somatostatin agonists and antagonists for treating diseases related to the eye

Country Status (10)

Country Link
EP (1) EP1019050B1 (ja)
JP (1) JP2002515912A (ja)
AT (1) ATE214604T1 (ja)
AU (1) AU7907198A (ja)
DE (1) DE69804332T2 (ja)
DK (1) DK1019050T3 (ja)
ES (1) ES2174447T3 (ja)
PT (1) PT1019050E (ja)
WO (1) WO1998058646A1 (ja)
ZA (1) ZA985410B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2246791A1 (en) * 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
EP1318994B1 (en) 2000-09-20 2008-02-27 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
US6518287B2 (en) 2000-09-20 2003-02-11 Schering Corporation Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
AU2001291040A1 (en) 2000-09-20 2002-04-02 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
CA2422729A1 (en) 2000-09-20 2002-06-06 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
KR20050059319A (ko) * 2002-10-31 2005-06-17 센주 세이야꾸 가부시키가이샤 각막 장해 치료제

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525793A (ja) * 1996-05-14 2001-12-11 ノボ ノルディスク アクティーゼルスカブ ソマトスタチンの作動因子及び拮抗因子
ZA979701B (en) * 1996-10-31 1998-05-21 Novo Nordisk As Novo Nordisk A Constrained somatostatin agonists and antagonists.Constrained somatostatin agonists and antagonists.

Also Published As

Publication number Publication date
DE69804332D1 (de) 2002-04-25
JP2002515912A (ja) 2002-05-28
DK1019050T3 (da) 2002-07-08
ES2174447T3 (es) 2002-11-01
EP1019050B1 (en) 2002-03-20
WO1998058646A1 (en) 1998-12-30
EP1019050A1 (en) 2000-07-19
DE69804332T2 (de) 2002-11-07
PT1019050E (pt) 2002-09-30
AU7907198A (en) 1999-01-04
ATE214604T1 (de) 2002-04-15

Similar Documents

Publication Publication Date Title
Lin et al. Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma
EP0743852B1 (en) Treatment of normotensive glaucoma with valsartan
DK1239774T3 (da) Apparat til behandling af öjensygdomme
CA2331053A1 (en) Compositions and methods for treating conditions responsive to estrogen
WO2003047513A3 (en) Method for treating ocular hypertension
DE60307607D1 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
US20100130569A1 (en) Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
HK1069851A1 (en) Bone morphogenic proteins (bmp), bmp receptors andbmp binding proteins and their use in the diagnosis and treatment of glaucoma
SG189177A1 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
JP2008505173A (ja) 痛みおよび他のα２アドレナリン作動性仲介状態を処置するための方法および組成物
WO2010113753A1 (ja) ＪＮＫ（ｃ－Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを用いた網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、ならびに、その使用
US20110130388A1 (en) Prophylactic or therapeutic agent for axial myopia
ZA985410B (en) Use of somatostatin agonists and antagonists for treating diseases related to the eye
ATE487514T1 (de) 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
US10485786B2 (en) Pharmaceutical composition for preventing or treating macular degeneration
JP2004182723A (ja) Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
HK1061645A1 (en) 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US20170360782A1 (en) Pharmacotherapy for preventing or treating glaucoma
Kaneko et al. Additive intraocular pressure-lowering effects of ripasudil with glaucoma therapeutic agents in rabbits and monkeys
CN113227086A (zh) 作为用于治疗神经视网膜疾病的视网膜前体细胞的生产的刺激剂的n-(4-(噁唑-5-基)苯基)色满-3-甲酰胺衍生物及相关化合物
WO2003057214A8 (en) Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
EP1359910A1 (en) Method for treating glaucoma ii b
JP2008285478A (ja) アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤
WO2004047868A1 (ja) Limキナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤
AU656547B2 (en) Use of pyridine derivatives in the treatment of ocular hypertension